Analyst Michael Matson of Needham maintained a Buy rating on LivaNova, retaining the price target of $64.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Michael Matson has given his Buy rating due to a combination of factors including the potential impact of LivaNova’s aura6000 hypoglossal nerve stimulation device for obstructive sleep apnea. The device is currently under review for premarket approval, with a decision anticipated in the first half of 2026. The obstructive sleep apnea market is substantial, with an estimated 54 million affected individuals in the United States, and the hypoglossal nerve stimulation serves as a secondary treatment option for approximately 1 million people.
Despite potential challenges from GLP-1s, which have been noted by Inspire Medical, the market for hypoglossal nerve stimulation remains significant. LivaNova is expected to capture market share from competitors like Inspire Medical, which has projected 2025 sales growth. Matson’s analysis suggests that the aura6000 device could contribute to LivaNova’s revenue and earnings per share growth, enhancing the company’s financial performance from 2026 to 2029.
According to TipRanks, Matson is an analyst with an average return of -5.3% and a 39.96% success rate. Matson covers the Healthcare sector, focusing on stocks such as TransMedics Group, Merit Medical Systems, and Medtronic.